

# INSIGHTS OF THE FUTURE now

We're coming for you, cancer.

## AVENIO Tumor Tissue CGP Panel V2

The 335-gene panel is aligned with the FoundationOne® CDx panel design and has genes with full coding exonic regions for the detection of Single Nucleotide Variants (SNVs), Insertions and Deletions (InDels), Copy Number Alterations (CNAs) and Rearrangements (REs).<sup>1</sup>

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1# (FAM123B or WTX)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	B2M	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DICER 1	DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3
EPHB1	EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1
ETV6	EZH2	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10
FGF12	FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2
FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FOXL2#	FUBP1	GABRA6
GATA3	GATA4	GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAQ	GNAS	GRM3
GSK3B	H3-3A (H3F3A)	HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1
IDH2	IGF1R	IKBKE	IKZF1	IKZF3	IKZF3	INPP4B	IRF2	IRF4
IRS2	JAK1	JAK2	JAK3	JUN	KDM5A	KDM5C	KDM6A	KDR
KEAP1	KEL	KIT	KLHL6	KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN
MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4	MAP3K1	MAP3K13	MAPK1	MCL1	MDM2
MDM4	MED12	MEF2B	MEN1	MERTK	MET	MITF	MKNK1	MLH1
MPL	MRE11 (MRE11A)	MSH2	MSH3	MSH6	MST1R	MTAP	MTOR	MUTYH
MYC	MYCL (MYCL1)	MYCN	NBN	MYD88	NF1	NF2	NFE2L2	NFKBIA
NKX2-1	NOTCH1	NOTCH2	NOTCH3	NOTCH4	NPM1	NRAS	NSD2 (WHSC1 or MMSET)	NSD3 (WHSC1L1)
NT5C2	NTRK1	NTRK2	NTRK3	P2RY8#	PALB2	PARP1	PARP2	PARP3
PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA	PDGFRB	PK1	PIK3C2B	PIK3C2G
PIK3CA	PIK3CB	PIK3R1	PIM1	PLCG2	PMS2	POLD1	POLE	PPARG
PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PRKN (PARK2)	PTCH1	PTEN	PTPN11
PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C	RAD51D	RAD52
RAD54L	RAF1	RARA	RB1	RBM10	REL	RET	RICTOR	RNF43
ROS1	RPTOR	RUNX1	SDHA	SDHB	SDHC	SDHD	SETD2	SF3B1
SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOC31#	SOX2
SOX9	SPEN	SPOP	SRC	SRSF2	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TENT5C# (FAM46C)	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14
TP53	TBX3	TP53BP1	TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL
WT1	XPO1	XRCC2	ZEB2	ZNF217	ZNF703	ZRSF2		

### Select Additional Rearrangements<sup>1,2</sup>

Genes with select intronic regions for the detection of select additional gene rearrangements, one gene with a promoter region and one non-coding RNA gene.

RARA	RSPO2	TERC*	BCL2	BRCA1	FGFR2	EGFR	ETV6	FGFR1
KIT	MYB	PDGFRA	RET	SDC4	TERT (promoter only)**	BCR	BRCA2	ETV4
EWSR1	FGFR2	KMT2A (MLL)	MYC	NTRK2	RAF1	ROS1	SLC34A21	TMPRSS2


# INSIGHTS OF THE FUTURE now

We're coming for you, cancer.

## CGP offers the greatest insights from a single assay

Our understanding of the genomic landscape of cancer continues to expand. The majority of cancer research is now focused on targeted therapies and biomarkers; as a result, CGP is becoming the tool of choice.<sup>2</sup>

Up to **93** unique CGP relevant biomarkers across **all solid tumors** by 2028\*



\* Multiple secondary sources used to cross validate information, including Trialrove, clinictrials.gov, EudraCT, ChiCTR; FDA approval timeline estimation based on Ph3 PCD + 8 months review; analysis based on current Phase 1/2, Phase 2 and Phase 3 trials with inclusion criteria requiring patient selection based on alterations to specific biomarkers; assumption made that all ongoing trials will lead to approval.

The AVENIO Tumor Tissue CGP Kit V2 detects all four genomic alterations and four genomic signatures including HRD with a 5-day turnaround time.<sup>1</sup>

### Genomic Alterations

- Single Nucleotide Variants (SNVs)
- Insertions and Deletions (InDels)
- Rearrangements (REs)
- Copy Number Alterations (CNAs)

### Genomic Signatures

- Microsatellite Instability (MSI)
- Tumor Mutational Burden (TMB)
- genomic Loss of Heterozygosity (gLOH)
- Homologous Recombination Deficiency signature (HRDsig)

For Research Use Only. Not for use in diagnostic procedures.

1. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use June 2024.  
2. Data on file at Roche.

© 2024 F. Hoffmann-La Roche Ltd.

AVENIO is a registered trademark of Roche. FOUNDATIONONE is a registered trademark of Foundation Medicine, Inc. All other product names and trademarks are the property of their respective owners.

For more information on the AVENIO Tumor Tissue CGP Kit V2 please visit [go.roche.com/aveniocgpkit](https://go.roche.com/aveniocgpkit) or contact your local Roche Sequencing representative.

**AVENIO** Tumor Tissue CGP Kit V2  
Powered by **FOUNDATION MEDICINE**